Friday, May 1, 2026

West Point: America’s Premier Forge of Military Leaders

On July 4, 1802, the United States...

The Future is Now: Chinese Cars to Dominate Global Market by 2030

Consulting firm AlixPartners predicted that one out...

BLIND LIES: North Korea’s FREE Housing Is A Vicious Lie To Cover The Real Cost Of Human Suffering

North Korea's Rodong Sinmun promotes the party's housing policies, claiming it uniquely provides free housing for workers, enhancing national pride.

Tag: Oncology

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

Next-Gen Cancer Drug Nesuparib: How It Outperforms Olaparib in SCLC and Pancreatic Cancer

Onconic Therapeutics will present Nesuparib research at AACR 2026, showcasing its potential for various cancers and overcoming PARP inhibitor limitations.

Proton Therapy for Liver Cancer: Revolutionary Results from Samsung Medical Center

Samsung Medical Center's proton therapy shows high effectiveness for liver cancer, offering hope for patients unsuitable for standard treatments.

SK Biopharmaceuticals Unveils Breakthrough Findings on NTSR1-Targeted Radiopharmaceutical SKL35501

SK Biopharmaceuticals will present findings on NTSR1-targeted treatments at the AACR Annual Meeting, showcasing innovative oncology research.

Daejeon University’s Seoul Oriental Hospital Earns “Integrated Cancer Certification” – What This Means for Patients

Daejeon University's Seoul Oriental Hospital gains recognition as a Certified Integrative Cancer Center for its innovative treatment methods.

Your Guide to Jaqbo: The New GERD Treatment Shaping the Future of Chronic Care

Onconic Therapeutics begins a Phase 3 trial for Jaqbo, aiming to expand GERD treatment options and enhance long-term management strategies.

LG Chem’s FMC-220: A Breakthrough Cancer Drug Targeting the p53 Y220C Mutation

LG Chem secures exclusive rights to FMC-220, a cancer drug targeting the p53 Y220C mutation, aiming for Phase 1 trials.

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

SK Biopharm’s 2026 Sales Meeting: Key Strategies for Senolamate’s Global Success

SK Biopharm's U.S. subsidiary held its annual sales meeting, focusing on growth strategies and collaboration for Cenobamate's success.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.